A post hoc analysis from the canagliflozin and renal events in diabetes with established nephropathy clinical evaluation trial showed that in patients with type 2 diabetes and CKD, the early reduction in albuminuria explained 48% of the effect of canagliflozin in reducing the risk of kidney failure.9 These data suggest that in patients with type 2 diabetes, the early change in albuminuria during SGLT2 inhibition explained part of the long-term clinical benefit and may be used to monitor long-term prognosis. This evidence concerns the gene SLC5A2 and kidney failure.